Click here to register for sp2 Inter-Active FREE OF CHARGE


Novartis to restructure US business Events


9-13 January 2012 PepTalk 2012 San Diego, CA, USA www.chi-peptalk.com


6-7 February 2012 Developing Chemical Processes for Active Pharmaceutical Ingredients Mumbai, India www.scientificupdate.co.uk


14-17 February 2012 InformexUSA New Orleans, LA, USA www.informex.com


19-21 March 2012 Organic Process Research and Development San Francisco, CA, USA www.scientificupdate.co.uk


21-23 March 2012 CPhI Japan Tokyo, Japan www.cphijapan.com


21-23 March 2012 ICSE Japan Tokyo, Japan www.icsejapan.com


17-18 April 2012 Dynamic Outsourcing for Life Sciences Cambridge, UK www.avakado.eu


17-18 April 2012 The Peptide Conference 2012 Cambridge, UK www.avakado.eu


14-16 May 2012 Modern Synthetic Methods & Chiral Europe


Prague, Czech Republic www.scientificupdate.co.uk


Novartis Pharmaceuticals is planning a restructure of its US business in anticipation of the patent expiration of its hypertension medication Diovan® (valsartan) and an expected reduction in demand for its type 2 diabetes treatment Rasilez®/Tekturna® (aliskiren) following termination of the ALTITUDE clinical study. The company is to reduce its cost base with current restructuring focused on the US market. “We recognise that the next two years will be challenging in the Pharmaceuticals Division and we are proactively making these changes to further focus our pipeline on the best opportunities and align our market position on our growth brands,” said David Epstein, division head of Novartis Pharmaceuticals. “These are difficult but necessary decisions that will free up resources to invest in the future of our business which we view as well suited to bring new valuable therapies to patients and payors.”


A central element of the plan is New batch reactors


catalogue from Syrris Syrris has released its new batch chemistry reactors catalogue. The range covers a broad spectrum of applications from synthesis, process optimisation and reaction analysis to crystallisation, calorimetry and scale-up . Syrriss automated reactor system, Atlas, is a series of modular products offering control of single or multiple reactions with volumes ranging from 1ml to 5 litres. Further information www.syrris.com


OctoPlus obtains drug development and manufacturing contract with Ferring Pharmaceuticals existing therapies.


OctoPlus NV has signed a formulation development and manufacturing contract with Ferring Pharmaceuticals A/S, which is expected to make a significant contribution to OctoPlus’ 2012 revenues. OctoPlus is a specialist in the


development and manufacture of improved injectable pharmaceuticals based on proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than


12 sp2 Inter-Active January/February 2012


The company is also focused on the development of long- acting, controlled release versions of known protein therapeutics, peptides and small molecules, including speciality generics.


The company provides advanced drug formulation and clinical-scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to- formulate active pharmaceutical ingredients.


a restructuring of the General Medicines business in the US market, where Novartis Pharmaceuticals will continue to focus on expanding its presence in speciality businesses aligned with the product portfolio and pipeline. As a result, the field force is planned to be reduced by about 1,630 positions and headquarters functions will realign to support the new organisation, resulting in an additional reduction of about 330 positions. The changes are planned to take effect in the second quarter of 2012. Placement and other support services will be available to affected employees, as well as redeployment opportunities, where they exist, within the Novartis Group of companies. The restructuring was prepared to respond to the loss of patent exclusivity for Diovan, expected in the USA in September 2012. The plan has been accelerated after the ALTITUDE study was halted following the recommendation from the Data Monitoring Committee overseeing the trial.


NEWS


The study was investigating Rasilez/Tekturna in a high-risk population of patients with type 2 diabetes and renal impairment. As a precautionary measure, Novartis Pharmaceuticals ceased all promotion of Rasilez/Tekturna- based products for use in combination with an angiotensin- converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). Novartis Pharmaceuticals, in consultation with health authorities, is now recommending that hypertensive patients with diabetes should not be treated with Rasilez/Tekturna in combination with an ACE inhibitor or ARB.


The restructuring is expected to result in an exceptional charge of about $160 million to be recognised in the results for the first quarter of 2012. It is planned to produce full-year savings of about $450 million as of 2013, about half of which is expected to be realised in 2012 due to reorganisation timelines. Together with ongoing productivity programmes, the company plans to continue to ensure that the product portfolio and research pipeline are fully invested in to sustain growth.


SAMPLE


Page 1  |  Page 2  |  Page 3  |  Page 4